Screener
Tandem Diabetes Care TNDM Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Tandem Diabetes Care in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Tandem Diabetes Care’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001438133-26-000125
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Operating lease and other impairment charges | — | 6,697 |
| Amortization of discount or (accretion of premium) on short-term investments | (1,821) | (1,780) |
| Loss from equity method investment | 9,506 | 6,917 |
| Stock-based compensation expense | 31,400 | 51,130 |
| Acquired in-process research and development expenses | — | 75,217 |
| Other | 1,005 | 424 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable, net | (3,082) | (13,516) |
Item 1. Financial Statements.
FAQ
- What is Tandem Diabetes Care's stock-based comp?
- Tandem Diabetes Care (TNDM) reported stock-based comp of $15.74M in Q2 2026.
- How has Tandem Diabetes Care's stock-based comp changed year-over-year?
- Tandem Diabetes Care's stock-based comp decreased by 38.6% year-over-year, from $25.64M to $15.74M.
- What is the long-term trend for Tandem Diabetes Care's stock-based comp?
- Over 4 years (2021 to 2025), Tandem Diabetes Care's stock-based comp has grown at a 11.0% compound annual growth rate (CAGR), from $60.75M to $92.38M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Tandem Diabetes Care's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude